NEW YORK, March 10 (GenomeWeb News) - Shares in Sequenom were trading up 19.35 percent, or $.24, at $1.48 in unusually heavy volume late this afternoon after the company said its flagship MassArray genotyping platform helped a team of researchers uncover a gene mutation linked to age-related macular degeneration.

 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.